pharmaceutical-investing La Jolla Pharmaceutical Company Gets European Commission Approval for GIAPREZA
pharmaceutical-investing La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118
pharmaceutical-investing La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118
pharmaceutical-investing La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA
Eagle Energy Metals Corp. and Spring Valley Acquisition Corp. II Announce Effectiveness of Registration Statement and Record and Meeting Dates for Extraordinary General Meeting of Shareholders to Approve Proposed Business Combination
